相关实验视频

Updated: Jun 30, 2025

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

新型化学型NLRP3抑制剂,以高强度向CRID3结合口袋

Lieselotte Vande Walle¹, Madhukar Said², Oonagh Paerewijck¹

¹Laboratory of Medical Immunology, Department of Internal Medicine and Paediatrics, Ghent University, Ghent, Belgium.

Life science alliance

|March 22, 2024

概括

研究人员发现了新型NLRP3抑制剂 (NICs),它们能够有力地和选择性地阻断NLRP3炎症酶. 这些化合物提供了一种新的治疗途径,与现有治疗方法相比,它们显示出更好的疗效和更少的非目标效应.

科学领域:

免疫学免疫学免疫学
药理学药理学是指药理学的学科.
药用化学医学化学

背景情况:

在许多人类疾病中,NLRP3炎症酶是关键的调解者.
目前临床级NLRP3抑制剂主要基于硫基尿素化合物CRID3 (MCC950).

研究的目的:

确定和描述NLRP3抑制剂的新型化学类.
与CRID3.3相比,评估它们的效力,选择性和作用机制.

主要方法:

生物化学测试 (BRET) 来评估与NLRP3的物理相互作用.
结构建模以确定结合部位和形状.
在体外测试中使用人类单细胞和小鼠巨细胞.
在体内研究使用小鼠模型的LPS-endotoxemia.
对碳酸无水的目标外活性评估.

主要成果:

一个新的NLRP3抑制化合物 (NICs) 类展示了强大和选择性的抑制.
与CRID3相比,NIC与NLRP3结合在一个不同的构造中.
NIC-11和NIC-12缺乏CRID3对碳酸无水酶的非目标作用.
在体内,NIC-12降低了IL-1β水平,并且在患者衍生细胞中显示出比CRID3强度大十倍.

结论:

这项研究引入了一种新型化学类型的高强度和选择性NLRP3抑制剂.
这些NIC具有明确的机制,与CRID3相比,它们具有优势.
NIC代表了开发新的NLRP3向疗法的有前途的化学线索.

更多相关视频

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b

Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b

Published on: November 11, 2016

相关概念视频

CRISPR and crRNAs

CRISPR and crRNAs

Bacteria and archaea are susceptible to viral infections just like eukaryotes; therefore, they have developed a unique adaptive immune system to protect themselves. Clustered regularly interspaced short palindromic repeats and CRISPR-associated proteins (CRISPR-Cas) are present in more than 45% of known bacteria and 90% of known archaea.
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...